| 刘伟欣,赵丹,黄州,等.早期结外鼻型NK/T细胞淋巴瘤放化疗疗效与不良反应分析[J].中华放射医学与防护杂志,2021,41(8):615-621.Liu Weixin,Zhao Dan,Huang Zhou,et al.Efficacy and toxicities of chemoradiotherapy in the treatment of early stage extranodal nasal-type NK/T-cell lymphoma[J].Chin J Radiol Med Prot,2021,41(8):615-621 |
| 早期结外鼻型NK/T细胞淋巴瘤放化疗疗效与不良反应分析 |
| Efficacy and toxicities of chemoradiotherapy in the treatment of early stage extranodal nasal-type NK/T-cell lymphoma |
| 投稿时间：2021-04-21 |
| DOI：10.3760/cma.j.issn.0254-5098.2021.08.009 |
| 中文关键词: 结外鼻型NK/T细胞淋巴瘤 放射治疗 疗效 不良反应 |
| 英文关键词:Extranodal nasal-type NK/T-cell lymphoma Radiotherapy Outcome Toxicity |
| 基金项目: |
|
| 摘要点击次数: 2919 |
| 全文下载次数: 1520 |
| 中文摘要: |
| 目的 探讨早期结外鼻型NK/T细胞淋巴瘤放化疗综合治疗的疗效及不良反应。方法 回顾性分析本院收治的174例经病理证实的结外鼻型NK/T细胞淋巴瘤患者资料。生存分析及组间比较采用Kaplan-Meier法和Log-rank检验。结果 全组Ⅰ期患者102例，Ⅱ期患者72例。2例患者接受单纯放疗，172例患者接受放化疗综合治疗。全组总有效率为94.2%（164/174），其中完全缓解（CR）患者153例（87.9%）。5年总生存率（OS）为87.3%，5年无进展生存率（PFS）为83.1%，5年局部区域控制率为91.9%。放化疗期间最常见不良反应为骨髓抑制和口腔黏膜炎，≥ 3级骨髓抑制占62.1%，≥ 3级口腔黏膜炎占10.9%。多因素分析结果显示，高龄、B症状及Ann Arbor分期Ⅱ期是OS的独立预后不良因素，而高龄和Ann Arbor分期Ⅱ期是PFS的独立预后不良因素。放疗剂量≥ 50 Gy较低剂量组可显著提高总PFS，两组5年PFS分别为83.5%和76.5%（HR 0.374，95%CI 0.169~0.826，P=0.015）。结论 早期NK/T细胞淋巴瘤经过放化疗综合治疗可达到较好疗效，不良反应可以耐受。 |
| 英文摘要: |
| Objective To assess the efficacy and toxicity of chemoradiotherapy in the treatment of early stage extranodal nasal-type NK/T-cell lymphoma (ENKTCL).Methods Retrospective review was conducted for 174 patients with pathological proved early stage ENKTCL who were treated in the Department of Radiation Oncology, Peking University Cancer Hospital & Institute. The Kaplan-Meier survival analysis was adopted to calculate the local-regional control (LRC), overall survival (OS), and progression free survival (PFS), and the Log-rank test COX regression model were applied to univariate and multivariate analyses.Results The patients in this study included 102 and 72 patients diagnosed with Ann Arbor stage-Ⅰ and stage-Ⅱ, respectively. Among them, two patients received radiotherapy alone and 172 patients were treated with combined chemoradiotherapy. The overall response rate of all the patients was 94.2%, with a complete response (CR) rate of 87.9% (153). Furthermore, the rates of 5-year OS, PFS, and LRC were 87.3%, 83.1%, and 91.9%, respectively. The most common toxicities during the chemotherapy and radiotherapy included myelosuppression and oral mucositis, with grade ≥ 3 myelosuppression and grade ≥ 3 oral mucositis accounting for 62.1% and 10.9% of all patients, respectively. As shown by multivariate analysis, the adverse prognostic factors for OS included age > 60, B symptoms, and stage Ⅱ, while the adverse prognostic factors for PFS included age > 60 and stage Ⅱ. Meanwhile, the PFS rate was significantly improved by increasing the radiation dose (≥ 50 Gy vs.<50 Gy), and the 5-year PFS rates of the two groups were 83.5% and 76.5%, respectively[hazard ratio (HR) 0.374; 95% CI, 0.169-0.826; P=0.015].Conclusions A good therapeutic effect can be achieved for early stage NK/T-cell lymphoma and the toxicities after combined chemoradiotherapy can be tolerated. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|